As Globus Med (GMED) Share Price Rose, Menta Capital Lowered Its Stake by $898,014; Intercept Pharmaceuticals In (ICPT) Stake Maintained by Credit Suisse Ag

January 20, 2018 - By Clifton Ray

Credit Suisse Ag increased its stake in Intercept Pharmaceuticals In (ICPT) by 30.2% based on its latest 2017Q3 regulatory filing with the SEC. Credit Suisse Ag bought 44,578 shares as the company’s stock declined 12.60% while stock markets rallied. The institutional investor held 192,183 shares of the health care company at the end of 2017Q3, valued at $11.15M, up from 147,605 at the end of the previous reported quarter. Credit Suisse Ag who had been investing in Intercept Pharmaceuticals In for a number of months, seems to be bullish on the $1.45B market cap company. The stock increased 8.52% or $4.53 during the last trading session, reaching $57.72. About 1.53 million shares traded or 90.62% up from the average. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 14.52% since January 20, 2017 and is downtrending. It has underperformed by 31.22% the S&P500.

Menta Capital Llc decreased its stake in Globus Med Inc (GMED) by 38.07% based on its latest 2017Q3 regulatory filing with the SEC. Menta Capital Llc sold 30,966 shares as the company’s stock rose 10.32% with the market. The hedge fund held 50,368 shares of the health care company at the end of 2017Q3, valued at $1.50 million, down from 81,334 at the end of the previous reported quarter. Menta Capital Llc who had been investing in Globus Med Inc for a number of months, seems to be less bullish one the $4.19 billion market cap company. The stock increased 1.02% or $0.44 during the last trading session, reaching $43.5. About 518,546 shares traded. Globus Medical, Inc. (NYSE:GMED) has risen 30.88% since January 20, 2017 and is uptrending. It has outperformed by 14.18% the S&P500.

Investors sentiment decreased to 1.38 in 2017 Q3. Its down 0.19, from 1.57 in 2017Q2. It fall, as 18 investors sold GMED shares while 68 reduced holdings. 42 funds opened positions while 77 raised stakes. 64.77 million shares or 3.39% more from 62.65 million shares in 2017Q2 were reported. Ameriprise invested in 306,055 shares. Menta Capital Limited Co holds 0.22% of its portfolio in Globus Medical, Inc. (NYSE:GMED) for 50,368 shares. 12,088 are held by Old Natl State Bank In. First Interstate Bancorp owns 3,033 shares. Ubs Asset Mgmt Americas Incorporated has 206,491 shares. Advantus Capital Mgmt owns 9,109 shares for 0.01% of their portfolio. 22,596 are held by First Tru Advisors Ltd Partnership. Caxton Associate LP owns 15,400 shares. 554,699 were accumulated by Consonance Cap Lp. Arrowstreet Capital Partnership holds 0.01% or 94,700 shares. Gru One Trading Limited Partnership stated it has 2,778 shares. California State Teachers Retirement Systems stated it has 112,984 shares or 0.01% of all its holdings. Swiss State Bank holds 120,600 shares. Deutsche Bank Ag accumulated 1.21M shares. Northwestern Mutual Wealth holds 0% of its portfolio in Globus Medical, Inc. (NYSE:GMED) for 262 shares.

Menta Capital Llc, which manages about $2.11B and $682.29M US Long portfolio, upped its stake in Pure Storage Inc by 44,122 shares to 63,122 shares, valued at $1.01M in 2017Q3, according to the filing. It also increased its holding in Malibu Boats Inc (NASDAQ:MBUU) by 19,467 shares in the quarter, for a total of 40,918 shares, and has risen its stake in Skechers U S A Inc (NYSE:SKX).

Among 15 analysts covering Globus Medical Inc (NYSE:GMED), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Globus Medical Inc had 43 analyst reports since August 3, 2015 according to SRatingsIntel. Barclays Capital maintained the stock with “Equalweight” rating in Wednesday, July 27 report. The stock of Globus Medical, Inc. (NYSE:GMED) has “Perform” rating given on Wednesday, November 9 by Oppenheimer. The stock has “Underperform” rating by Bank of America on Friday, January 8. The firm earned “Hold” rating on Tuesday, September 26 by Needham. Barclays Capital maintained the shares of GMED in report on Thursday, August 3 with “Underweight” rating. The stock of Globus Medical, Inc. (NYSE:GMED) has “Sell” rating given on Monday, May 16 by Goldman Sachs. Piper Jaffray maintained the shares of GMED in report on Tuesday, January 2 with “Buy” rating. The rating was maintained by Piper Jaffray on Tuesday, July 18 with “Buy”. On Monday, October 23 the stock rating was maintained by Canaccord Genuity with “Buy”. The rating was downgraded by Leerink Swann on Wednesday, July 27 to “Market Perform”.

Analysts await Globus Medical, Inc. (NYSE:GMED) to report earnings on February, 26. They expect $0.34 EPS, up 9.68% or $0.03 from last year’s $0.31 per share. GMED’s profit will be $32.77M for 31.99 P/E if the $0.34 EPS becomes a reality. After $0.30 actual EPS reported by Globus Medical, Inc. for the previous quarter, Wall Street now forecasts 13.33% EPS growth.

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 2 Sell and 9 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 65 analyst reports since August 10, 2015 according to SRatingsIntel. Needham maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Friday, October 20 with “Hold” rating. The stock has “Buy” rating by Credit Suisse on Monday, September 25. The rating was downgraded by Needham on Friday, January 20 to “Hold”. The firm has “Mkt Perform” rating given on Wednesday, November 11 by FBR Capital. The company was maintained on Thursday, June 1 by Credit Suisse. Wells Fargo upgraded the stock to “Outperform” rating in Tuesday, April 5 report. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Outperform” rating by Credit Suisse on Wednesday, March 30. The firm has “Hold” rating by Needham given on Friday, September 15. Cantor Fitzgerald initiated it with “Sell” rating and $58 target in Wednesday, July 6 report. Morgan Stanley initiated the stock with “Underweight” rating in Thursday, August 13 report.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>